|
Biological Activity:
Reversine induces differentiated myogenic-lineage committed cells to become multipotent mesenchymal progenitor cells; it is a potent mitotic inhibitor of MPS1 kinase, which inhibits the spindle assembly checkpoint in a dose-dependent manner; also acts as A3 adenosine receptor antagonist (Ki: 660 nM) or aurora kinases inhibitor (IC50: 400-500 nM for Aurora A/B/C respectively).
References:
M Saraiya et al. Reversine Enhances Generation of Progenitor-like Cells by Dedifferentiation of Annulus Fibrosus Cells. Tissue Eng. Part A. 2010, 16(4), 1443–1455. [online]
S Santaguida etal. Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. J. Cell Biol. 2010, 190(1), 73-87. [online]
AM D'Alise et al. Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Mol. Cancer Ther. 2008, 7(5), 1140-1149. [online]
L Anastasia et al. Reversine-treated fibroblasts acquire myogenic competence in vitro and in regenerating skeletal muscle. Cell Death and Differentiation 2006, 13, 2042–2051. [online]
S Chen et al. Dedifferentiation of lineage-committed cells by a small molecule. J. Am. Chem. Soc. 2004, 126, 410-411.
M Perreira et al. Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J. Med. Chem. 2005, 48, 4910-4918.
Chemical Name: N6-cyclohexyl-N2-(4-morpholinophenyl)-9H-purine-2,6-diamine
| 
